Vol 9, No 2 (2024)
Letter to the Editor
Published online: 2024-06-28

open access

Page views 90
Article views/downloads 84
Get Citation

Connect on Social Media

Connect on Social Media

Senolytic effect of canagliflozin, a new possible line of treatment for age-related diseases

Jakub Cecot1, Konrad Zarzecki2, Miłosz Mandryk2
Medical Research Journal 2024;9(2):245-246.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Perkovic V, Jardine MJ, Neal B, et al. CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019; 380(24): 2295–2306.
  2. Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation. 2019; 140(9): 739–750.
  3. Ohkuma T, Van Gaal L, Shaw W, et al. Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program. Diabetes Obes Metab. 2020; 22(4): 530–539.
  4. Ye N, Jardine MJ, Oshima M, et al. Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: insights from the CREDENCE trial. Circulation. 2021; 143(18): 1735–1749.
  5. Katsuumi G, Shimizu I, Suda M, et al. SGLT2 inhibition eliminates senescent cells and alleviates pathological aging. Nat Aging. 2024 [Epub ahead of print].
  6. McHugh D, Gil J. Senescence and aging: Causes, consequences, and therapeutic avenues. J Cell Biol. 2018; 217(1): 65–77.